Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial

EuroIntervention. 2012 Jan;7(9):1060-1. doi: 10.4244/EIJV7I9A168.


Aim: The first-in-man ABSORB Cohort A trial demonstrated the bioresorption of the ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA) at two years. This report describes the 4-year clinical outcomes.

Methods and results: The ABSORB Cohort A trial enrolled 30 patients with a single de novo native coronary artery lesion. Clinical follow-up was available in 29 patients since one patient withdrew consent after the six month follow-up. At four years, the hierarchical ID-MACE of 3.4% remained unchanged. Clopidogrel therapy had been discontinued in all patients.

Conclusion: Four-year clinical results demonstrate a sustained low MACE rate (3.4%) without any late complications such as stent thrombosis.

Trial registration: NCT00300131.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood Vessel Prosthesis* / adverse effects
  • Cohort Studies
  • Coronary Artery Disease / therapy*
  • Drug-Eluting Stents* / adverse effects
  • Everolimus
  • Follow-Up Studies
  • Humans
  • Incidence
  • Longitudinal Studies
  • Myocardial Infarction / epidemiology
  • Risk Factors
  • Sirolimus / adverse effects
  • Sirolimus / analogs & derivatives*
  • Thrombosis / epidemiology
  • Tissue Scaffolds* / adverse effects
  • Treatment Outcome


  • Everolimus
  • Sirolimus

Associated data